Secondary objective outcomes at baseline and follow-up. Data are mean (standard deviation, n) unless otherwise indicated.
| Outcome . | Baseline . | Follow-up . | ||||||
|---|---|---|---|---|---|---|---|---|
| Four months . | 12 months . | |||||||
| REACH-HF . | Control . | REACH-HF . | Control . | REACH-HF . | Control . | Between-group difference . | p value . | |
| ISWT, m | 262.3 (153.4, 99) | 239.7 (152.4, 103) | 328.5 (181.3, 66) | 294.3 (215.5, 75) | 328.5 (181.3, 66) | 294.3 (215.5, 75) | 0.1 (–33.3 to 33.5) | 0.995 |
| Number of days/week with at least 10 min/day activity >100 milli-ga | 5.8 (2.3, 99) | 5.9 (1.9, 103) | 5.6 (2.4, 78) | 5.5 (2.6, 84) | 5.6 (2.4, 78) | 5.5 (2.6, 84) | 0.2 (–0.4 to 0.7) | 0.601 |
| Average time/day (min) | ||||||||
| ≤20 milli-ga | 1104 (102, 99) | 1106 (114, 103) | 1107 (110, 88) | 1092 (116, 93) | 1092 (124, 78) | 1103 (118, 84) | –7 (–29 to 15) | 0.534 |
| 21–40 milli-ga | 141 (35, 99) | 136 (35, 103) | 140 (35, 88) | 138 (30, 93) | 142 (39, 78) | 138 (34, 84) | –1 (–9 to 8) | 0.880 |
| 41–60 milli-ga | 80 (25, 99) | 80 (27, 103) | 80 (27, 88) | 82 (26, 93) | 81 (30, 78) | 81 (28, 84) | 0 (–6 to 6) | 0.901 |
| 61–80 milli-ga | 45 (21, 99) | 46 (21, 103) | 45 (22, 88) | 48 (22, 93) | 48 (23, 78) | 46 (22, 84) | 2 (–2 to 5) | 0.372 |
| 81–100 milli-ga | 26 (16, 99) | 27 (16, 103) | 26 (16, 88) | 28 (17, 93) | ||||
| >100 milli-ga | 42 (34, 99) | 46 (40, 103) | 43 (37, 88) | 51 (46, 93) | ||||
| Outcome . | Baseline . | Follow-up . | ||||||
|---|---|---|---|---|---|---|---|---|
| Four months . | 12 months . | |||||||
| REACH-HF . | Control . | REACH-HF . | Control . | REACH-HF . | Control . | Between-group difference . | p value . | |
| ISWT, m | 262.3 (153.4, 99) | 239.7 (152.4, 103) | 328.5 (181.3, 66) | 294.3 (215.5, 75) | 328.5 (181.3, 66) | 294.3 (215.5, 75) | 0.1 (–33.3 to 33.5) | 0.995 |
| Number of days/week with at least 10 min/day activity >100 milli-ga | 5.8 (2.3, 99) | 5.9 (1.9, 103) | 5.6 (2.4, 78) | 5.5 (2.6, 84) | 5.6 (2.4, 78) | 5.5 (2.6, 84) | 0.2 (–0.4 to 0.7) | 0.601 |
| Average time/day (min) | ||||||||
| ≤20 milli-ga | 1104 (102, 99) | 1106 (114, 103) | 1107 (110, 88) | 1092 (116, 93) | 1092 (124, 78) | 1103 (118, 84) | –7 (–29 to 15) | 0.534 |
| 21–40 milli-ga | 141 (35, 99) | 136 (35, 103) | 140 (35, 88) | 138 (30, 93) | 142 (39, 78) | 138 (34, 84) | –1 (–9 to 8) | 0.880 |
| 41–60 milli-ga | 80 (25, 99) | 80 (27, 103) | 80 (27, 88) | 82 (26, 93) | 81 (30, 78) | 81 (28, 84) | 0 (–6 to 6) | 0.901 |
| 61–80 milli-ga | 45 (21, 99) | 46 (21, 103) | 45 (22, 88) | 48 (22, 93) | 48 (23, 78) | 46 (22, 84) | 2 (–2 to 5) | 0.372 |
| 81–100 milli-ga | 26 (16, 99) | 27 (16, 103) | 26 (16, 88) | 28 (17, 93) | ||||
| >100 milli-ga | 42 (34, 99) | 46 (40, 103) | 43 (37, 88) | 51 (46, 93) | ||||
1000 milli-g = 1 g = 9.81 m/s2, < 40 milli-g is approximately equivalent to sedentary activities such as sitting, lying and ≥100 milli-g is approximately equivalent to activities undertaken at a moderate to vigorous intensity.
REACH-HF: Rehabilitation EnAblement in CHronic Heart Failure; ISWT: incremental shuttle walk test; milli-g: milli-gravity unit
Secondary objective outcomes at baseline and follow-up. Data are mean (standard deviation, n) unless otherwise indicated.
| Outcome . | Baseline . | Follow-up . | ||||||
|---|---|---|---|---|---|---|---|---|
| Four months . | 12 months . | |||||||
| REACH-HF . | Control . | REACH-HF . | Control . | REACH-HF . | Control . | Between-group difference . | p value . | |
| ISWT, m | 262.3 (153.4, 99) | 239.7 (152.4, 103) | 328.5 (181.3, 66) | 294.3 (215.5, 75) | 328.5 (181.3, 66) | 294.3 (215.5, 75) | 0.1 (–33.3 to 33.5) | 0.995 |
| Number of days/week with at least 10 min/day activity >100 milli-ga | 5.8 (2.3, 99) | 5.9 (1.9, 103) | 5.6 (2.4, 78) | 5.5 (2.6, 84) | 5.6 (2.4, 78) | 5.5 (2.6, 84) | 0.2 (–0.4 to 0.7) | 0.601 |
| Average time/day (min) | ||||||||
| ≤20 milli-ga | 1104 (102, 99) | 1106 (114, 103) | 1107 (110, 88) | 1092 (116, 93) | 1092 (124, 78) | 1103 (118, 84) | –7 (–29 to 15) | 0.534 |
| 21–40 milli-ga | 141 (35, 99) | 136 (35, 103) | 140 (35, 88) | 138 (30, 93) | 142 (39, 78) | 138 (34, 84) | –1 (–9 to 8) | 0.880 |
| 41–60 milli-ga | 80 (25, 99) | 80 (27, 103) | 80 (27, 88) | 82 (26, 93) | 81 (30, 78) | 81 (28, 84) | 0 (–6 to 6) | 0.901 |
| 61–80 milli-ga | 45 (21, 99) | 46 (21, 103) | 45 (22, 88) | 48 (22, 93) | 48 (23, 78) | 46 (22, 84) | 2 (–2 to 5) | 0.372 |
| 81–100 milli-ga | 26 (16, 99) | 27 (16, 103) | 26 (16, 88) | 28 (17, 93) | ||||
| >100 milli-ga | 42 (34, 99) | 46 (40, 103) | 43 (37, 88) | 51 (46, 93) | ||||
| Outcome . | Baseline . | Follow-up . | ||||||
|---|---|---|---|---|---|---|---|---|
| Four months . | 12 months . | |||||||
| REACH-HF . | Control . | REACH-HF . | Control . | REACH-HF . | Control . | Between-group difference . | p value . | |
| ISWT, m | 262.3 (153.4, 99) | 239.7 (152.4, 103) | 328.5 (181.3, 66) | 294.3 (215.5, 75) | 328.5 (181.3, 66) | 294.3 (215.5, 75) | 0.1 (–33.3 to 33.5) | 0.995 |
| Number of days/week with at least 10 min/day activity >100 milli-ga | 5.8 (2.3, 99) | 5.9 (1.9, 103) | 5.6 (2.4, 78) | 5.5 (2.6, 84) | 5.6 (2.4, 78) | 5.5 (2.6, 84) | 0.2 (–0.4 to 0.7) | 0.601 |
| Average time/day (min) | ||||||||
| ≤20 milli-ga | 1104 (102, 99) | 1106 (114, 103) | 1107 (110, 88) | 1092 (116, 93) | 1092 (124, 78) | 1103 (118, 84) | –7 (–29 to 15) | 0.534 |
| 21–40 milli-ga | 141 (35, 99) | 136 (35, 103) | 140 (35, 88) | 138 (30, 93) | 142 (39, 78) | 138 (34, 84) | –1 (–9 to 8) | 0.880 |
| 41–60 milli-ga | 80 (25, 99) | 80 (27, 103) | 80 (27, 88) | 82 (26, 93) | 81 (30, 78) | 81 (28, 84) | 0 (–6 to 6) | 0.901 |
| 61–80 milli-ga | 45 (21, 99) | 46 (21, 103) | 45 (22, 88) | 48 (22, 93) | 48 (23, 78) | 46 (22, 84) | 2 (–2 to 5) | 0.372 |
| 81–100 milli-ga | 26 (16, 99) | 27 (16, 103) | 26 (16, 88) | 28 (17, 93) | ||||
| >100 milli-ga | 42 (34, 99) | 46 (40, 103) | 43 (37, 88) | 51 (46, 93) | ||||
1000 milli-g = 1 g = 9.81 m/s2, < 40 milli-g is approximately equivalent to sedentary activities such as sitting, lying and ≥100 milli-g is approximately equivalent to activities undertaken at a moderate to vigorous intensity.
REACH-HF: Rehabilitation EnAblement in CHronic Heart Failure; ISWT: incremental shuttle walk test; milli-g: milli-gravity unit
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
